Treatment group will receive 1500 mg/day (three 500 mg tablets/day) of ß-D mannuronic acid orally for 12 weeks.

2 trials

Sponsors

Vice-Chancellor for Research, Tehran University of Medical Sciences

Conditions

Ankylosing spondylitis. Ankylosing spondylitisRheumatoid Arthritis. Seropositive Rheumatoid Arthritis

Phase 2

The therapeutic effects of ß-D-Mannuronic acid in patients with ankylosing spondylitis

Active, not recruitingIRCT2013062213739N1

Vice-Chancellor for Research, Tehran University of Medical SciencesAnkylosing spondylitis. Ankylosing spondylitis

Start: 2014-04-20Target: 35Updated: 2018-02-22

The therapeutic effects of ß-D-Mannuronic acid in patients with Rheumatoid Arthritis

Active, not recruitingIRCT2014011213739N2

Vice-Chancellor for Research, Tehran University of Medical SciencesRheumatoid Arthritis. Seropositive Rheumatoid Arthritis

Start: 2014-07-20Target: 35Updated: 2018-02-22

Related Papers

Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property

Endocrine Metabolic & Immune Disorders - Drug Targets2018-08-288 citations

Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial.

2017-11-0820 citations

Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis.

2017-10-239 citations

The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.

2017-08-178 citations

Effects of &beta;-D-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on <em>IL17</em>, <em>ROR&gamma;t</em>, <em>IL4 </em>and <em>GATA3 </em>gene expressions in rheumatoid arthritis patients

Drug Design Development and Therapy2017-03-0126 citations

The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.

2017-01-019 citations